1. Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune evasion mechanisms
- Author
-
Henrik J. Johansson, Marija Kotevska, Rui M. M. Branca, Sofi Isaksson, Krishna Pinganksha Purohit, Carsten G. Hansen, Mohammad Pirmoradian, Georgios Mermelekas, Odd Terje Brustugun, Olena Berkovska, David Tamborero, Richard Cunningham, Husen M. Umer, Janne Lehtiö, Yanbo Pan, Maria Planck, Åslaug Helland, Lukas M. Orre, Fabio Socciarelli, Taner Arslan, Anna Karlsson, Mats Jönsson, Elsa Arbajian, Hassan Foroughi Asl, Vilde Drageset Haakensen, Ioannis Siavelis, Mattias Aine, Johan Staaf, and Hans Brunnström
- Subjects
Cancer Research ,Lung Neoplasms ,STK11 ,Biology ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Carcinoma, Non-Small-Cell Lung ,medicine ,Humans ,Lung cancer ,030304 developmental biology ,Immune Evasion ,Proteogenomics ,0303 health sciences ,Cancer ,Fibrinogen ,Genomics ,medicine.disease ,Phenotype ,3. Good health ,HNF1A ,Oncology ,030220 oncology & carcinogenesis ,Proteome ,Cancer research - Abstract
Despite major advancements in lung cancer treatment, long-term survival is still rare and a deeper understanding of molecular phenotypes would allow the identification of specific cancer dependencies and immune-evasion mechanisms. Here we performed in-depth mass-spectrometry-based proteogenomic analysis of 141 tumors representing all major histologies of non-small cell lung cancer (NSCLC). We identified six distinct proteome subtypes with striking differences in immune cell composition and subtype-specific expression of immune checkpoints. Unexpectedly, high neoantigen burden was linked to global hypomethylation and complex neoantigens mapped to genomic regions, such as endogenous retroviral elements and introns, in immune-cold subtypes. Further, we linked immune evasion with LAG-3 via STK11 mutation-dependent HNF1A activation and FGL1 expression. Finally, we develop a data-independent acquisition mass-spectrometry-based NSCLC subtype classification method, validate it in an independent cohort of 208 NSCLC cases and demonstrate its clinical utility by analyzing an additional cohort of 84 late-stage NSCLC biopsy samples. Lehtio and colleagues perform proteogenomic analysis of non-small cell lung cancer and identify molecular subtypes with distinct immune-evasion mechanisms and therapeutic targets and validate their classification method in separate clinical cohorts.
- Published
- 2021
- Full Text
- View/download PDF